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Poster Session I S217In cord blood bank practice, the 6 obstetric factors given above
and CBU weight are generally known before the decision on further
processing is made. In the respective regression model with TNC as
dependent variable, the highest absolute b values were reached for
CBU weight (b5 0.70) and vaginal delivery (b5 0.33) followed by
the number of preceding pregnancies (b5-0.13). These factors
were also significant at p5 0.05.
The presented data can be applied to optimize cord blood bank
operations. As one result one could, for example, establish different
CBUminimumweights for further processing subject to birth route:
since CBUs from vaginal deliveries have higherWBC counts, the re-
spective minimum weight could be lower than that of CBUs from
sectios.159
DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION ACHIEVES UNI-
VERSAL ENGRAFTMENT BUT IS ASSOCIATED WITH CONSIDERABLE
TRANSPLANT-RELATED MORTALITY
Baltadakis, I., Karakasis, D., Manaka, A., Panitsas, F., Poulopoulou, Z.,
Delistrati, V., Bika, E., Garofalaki, M., Papageorgiou, M.,
Vasileiou, S., Gigantes, S., Apostolidis, J., Harhalakis, N.,
Nikiforakis, E. Evangelismos Hospital, Athens, Greece
The applicability of umbilical cord blood transplantation (UCBT)
is limited by inadequate cell dose especially for adult patients. Infu-
sion of 2 partially HLA-matched units has been shown to facilitate
engraftment, and allows for transplantation of patients for whom
a single unit of sufficient cell dose is not available. However, double
UCBT is associated with an increased risk of acute graft-versus-host
disease (aGVHD), which may impair the outcomes. From 8/2006 to
7/2009, 21 patients (female:male5 10:11) with high-risk acute mye-
loid (AML, n5 16) or lymphoblastic (ALL, n5 5) leukemia received
double UCBT in our center. The patients had a median age of 36
years (range: 16-60), and a median weight of 75 kg (range: 53-105).
The median time from diagnosis to UCBT was 10 months (range:
3-91). The disease phase at transplant was 1st complete remission
(CR1) in 10 patients, CR2 in 5, and $CR3 or resistant relapse in
6. The conditioning regimen was myeloablative in 16 (TBI-based:
7, busulfan-based: 9), and reduced-intensity in 5 patients. ATG
was administered during conditioning only in 1 patient. Cyclospor-
ine plus mycophenolate mofetil was used for aGVHD prophylaxis.
The majority of UCB units (34/42) were 4/6 antigen matched to re-
cipient at HLA-A, -B, and -DRB1. The median total doses of nucle-
ated andCD34+ cells at infusionwere 4.3 10^7/kg (range: 2.65-5.4
 10^7/kg) and 1.33  10^5/kg (range: 0.6-3.1  10^5/kg), respec-
tively. Neutrophil recovery was achieved in all but 1 patient at a me-
dian of 19 days [cumulative incidence (CI) by day 52, 95%]. The CI
of platelet recovery (.50,000/uL) was 62% by day 270, and occurred
at a median of 83 days (range: 32-193). Eighteen patients (CI, 85%)
developed aGVHD (grade II-IV: 18, III-IV: 5). Three of 12 evalu-
able patients, who survived for more than 100 days, developed
chronic GVHD (CI, 14%). Treatment-related mortality (TRM)
was 38% at day 100 and 52% at 1 year. Causes of TRM were infec-
tion (n5 6), GVHD (n5 3), and transplant-associated microangi-
opathy (n5 2). Disease relapse occurred in 5 patients (CI, 28.5%
at 1 year). The 2-year disease-free and overall survival is 24% and
28%, respectively. Five patients are alive and in CR, 10-38 months
after UCBT. In conclusion, double UCBT results in an excellent
rate of engraftment in adult recipients. However, further improve-
ments should focus on the reduction of early TRM, which is signif-
icantly high and might be attributed to the increased incidence of
aGVHD.160
FLUDARABINE, CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN
(ATG) AS CONDITIONING REGIMEN IN MATCHED RELATED AND UNRE-
LATED ALLOGENEIC STEM CELL TRANSPLANTATION FOR SEVERE
APLASTIC ANEMIA (SAA): THE M.D. ANDERSON CANCER CENTER TEN-
YEAR EXPERIENCE
Anderlini, P., Acholonu, S., Okoroji, G., Popat, U., Giralt, S.A.,
Shpall, E.J., Qazilbash, M., de Lima, M., Worth, L., Champlin, R.E.
The University of Texas M.D. Anderson Cancer Center, Houston, TXBackground: Total body irradiation (TBI) is often employed in
matched unrelated donor (MUD) allogeneic stem cell transplanta-
tion (allo-SCT) in SAA. However, even at low doses, TBI can cause
serious short- and long-term toxicities. In matched related donors
(MRD), outcome in SAA patients$ 40 years with high-dose cyclo-
phosphamide (CY)6ATG is poor due to graft rejection, GVHD
and organ failure. Aim: To explore feasibility of a fludarabine
(FLU)–based, high-dose ATG, TBI-free regimen in MUD (all
ages) and MRD (recipient. 40 years) allo-SCT.
Methods:Over a 10-year period (1999-2009), twenty SAA patients
underwent allo-SCT with a FLU-CY-ATG regimen from a MRD
(n5 7, all age$ 40) or a MUD (n5 13, any age). Median age was
34 years (range 1-59). Seven pts (33%) were$ 50 years old. Bone
marrow was used as SC source in all but four patients. Once the
regimen was standardized, it included (n5 13) FLU (30 mg/m
sq  4 days) intravenously (IV), CY (300 mg/m sq IV  4 days),
and thymoglobulin (THY, 3.75 mg/kg IV  3-4 days). Before
that, in seven patients doses were FLU 20-50 mg/m sq IV  4
days; CY 40-60 mg/kg IV  2-4 days; ATG IV 20-30 mg/kg
(horse product) or 3 mg/kg (THY) x 2-4 days. Median time
from diagnosis to allo-SCT was 12 months (2-244). Eleven pa-
tients (55%) were transplanted off study (active infection, poor or-
gan function, etc).
Results: Seventeen out of 19 evaluable patients engrafted (90%).
There were two secondary graft failures (10%). Median time to neu-
trophil recovery (i.e. absolute neutrophil count$ 500/mL) was 15
days (range 8-30). Chimerism studies indicated $90% donor-de-
rived engraftment in 16/19 evaluable patients (75%) and thirteen pa-
tients were 100% donor. Four out of 20 evaluable patients (20%)
developed acute grade II-IV GVHD, and 6/16 evaluable patients
(37%) developed chronic GVHD. Thirteen patients (62%) are alive
(including eight out of the last nine treated) with a median follow-up
of 30 months (3-112). Seven patients expired (graft rejection n5 1,
infection n5 2, GVHDn5 1, organ failure n5 1, EBV lymphopro-
liferative disorder/LPD n5 2). There was one early death (death\
day +30) and no known late graft failures.
Conclusion: Fludarabine-based, TBI-free for MRD and MUD
allo-SCT is feasible in this high-risk group (older age, active infec-
tion, poor organ function, etc), with high engraftment rates and
low early mortality. Presumably due to high-dose ATG, GVHD-
related incidence and mortality were low, although EBV LPD
was a drawback.161
MULTIPLE UNIT UMBILICAL CORD BLOOD TRANSPLANTATION (MU
UCBT) WITH TOTAL BODY IRRADIATION, ETOPOSIDE AND ANTITHYMO-
CYTE GLOBULIN FOR ADULT HEMATOLOGIC MALIGNANCY PATIENTS
Sobecks, R., Copelan, E., Kalaycio,M., Askar,M., Rybicki, L., Serafino, S.,
Serafin,M., Macklis, R., Dean, R., Pohlman, B., Andresen, S., Bolwell, B.
Cleveland Clinic, OH
MU UCBT is an alternative donor transplant approach for adult
hematologic malignancy (HM) pts. TBI and VP16 is an effective
conditioning regimen, but its utility in MU UCBT is not well
known. From 10/03-2/09 we enrolled 16 adult HM pts on a trial
with this regimen prior to MU-UCBT. Eligibility included lack of
an HLAmatched related or unrelated donor. Pts had to have at least
a 4/6HLAmatchedUCB unit with at least 0.5 107 nucleated cells/
kg and a 2ndUCB unit with at least a 4/6HLAmatch to the 1st UCB
unit. The minimum required cryopreserved TNC dose for both
units was 1  107/kg or an infused CD34+ cell dose of 1.5  105/
kg. Pts received TBI 1,320 cGy (days -7 to -4), VP16 60 mg/kg
(day -3) and ATG 30 mg/kg (days -3 to +1). GVHD prophylaxis: ta-
crolimus and mycophenolate. Median age was 47 yrs (range, 18-60)
and diagnoses were 8 AML, 3 CML, 2MDS, 1 ALL, 1 CLL 1NHL.
Median time from diagnosis to UCBT was 8 mos. The 1st UCB unit
infused (UCB1) included five 4/6, ten 5/6 and one 6/6 HLAmatches
with the recipient, and for the 2nd UCB unit (UCB2) with recipient
there were one 3/6, five 4/6, and ten 5/6 matches. Median thawed
TNC doses infused for UCB1 and UCB2 were 1.6  107/kg and
1.2  107/kg, respectively; thawed CD34+ cell doses were 0.6 
105/kg for both units.12 were evaluable for engraftment; 3 others
